Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Satya Das MD

Satya Das MD

Clinical Instructor, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN

Dr. Das is a clinical instructor in the Department of Medicine at Vanderbilt University Medical Center, at the Vanderbilt-Ingram Cancer Center (VICC). His research interests are in the realm of gastrointestinal (GI) cancer and drug development. They specifically focus upon designing early phase studies to take advantage of salvage DNA repair pathway dependence in DNA damage response (DDR) deficient tumors and to overcome the immunosuppressive tumor microenvironment in refractory tumors through immunotherapy combinations. He has developed several protocols, spanning diseases such as gastric and gastroesophageal junction (GEJ) adenocarcinoma, neuroendocrine tumors, extra-pulmonary small cell carcinoma and pancreatic adenocarcinoma with his primary mentor Dr. Jordan Berlin who serves as the Associate Director of Clinical Investigation Strategy at VICC and the co-leader of the Gastrointestinal Cancer Research Program. He has also written protocols and grant submissions with secondary mentors Dr. Michael Gibson and Dr. Laura Goff, both associate professors in GI oncology at VICC, focused upon gastric adenocarcinoma and cholangiocarcinoma.

He is currently enrolled in the MSCI program at Vanderbilt University which has provided him with structured training in clinical trial design, biostatistics, data-management and precision medicine. He completed a drug development externship at the Investigational Drug Branch (IDB) of the National Cancer Institute (NCI) Cancer Therapeutics Evaluation Program (CTEP) which allowed him to work with IDB members such as Dr.Jeffrey Abrams, Dr.Jeffrey Moscow, Dr.Percy Ivy, Dr. Angela Chen, Dr.Charles Kunos and Dr. Austin Doyle, to review concept proposals and assess novel drug combinations.

Clinically, he focuses on caring for patients with advanced GI malignancies with a specific interest in those with neuroendocrine tumors, gastric cancer and colorectal cancer.